Myriad Genetics, Inc., has announced that its Prolaris test has been included in the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines) for all men with localized prostate cancer, regardless of their risk category. The NCCN guidelines provide treatment recommendations to ensure that patients receive diagnostic treatment and services that are likely to improve clinical outcomes.
The updated NCCN guidelines include the use of the Prolaris test to help patients better assess their risk of disease-specific mortality and biochemical recurrence. According to Myriad spokespersons, Prolaris is proven and validated based on gold-standard clinical endpoints of disease recurrence and prostate cancer-specific death in untreated men, thus identifying men who can safely forgo initial surgery or radiation and be managed with active surveillance; and proven in clinical utility studies to change treatment recommendations for up to 65 percent of prostate cancer patients in all risk categories.
Earlier this month, Myriad announced that Palmetto GBA, the Medicare administrative contractor, issued a draft LCD for the Prolaris test for patients with low-risk prostate cancer. Once finalized, the LCD will establish coverage policy for Medicare beneficiaries throughout the United States.
Prolaris is a 46-gene RNA-expression test that directly measures tumor cell growth characteristics for stratifying the risk of disease progression in prostate cancer patients. Prolaris provides a quantitative measure of the RNA expression levels of genes involved in the progression of tumor growth. Low gene expression is associated with a low risk of disease progression in men who may be candidates for active surveillance, and high gene expression is associated with a higher risk of disease progression in patients who may benefit from additional therapy. Learn more about the Prolaris test.
Read more
